Page 70 - ஜனநாயகவாதி கட்டுப்படுத்தப்படுகிறது காங்கிரஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tuesday, December 15, 2020 What a year for the Food and Drug Administration! FDA, an agency with regulatory oversight of 20-25% of products on which consumers spend, including food and medicines, but which typically stays out of the limelight, was thrust into the public eye amidst the COVID-19 pandemic. This was the year many Americans became familiar with lesser-known and niche policies like those governing emergency use authorizations (EUAs) and with the role of FDA in regulating laboratory developed tests (LDTs). The agency also took some flak for seeming to bow to political pressure in authorizing hydroxychloroquine for emergency use as a potential COVID-19 treatment, then rescinding the authorization, as well as for its less-than-accurate pronouncements of positive data concerning convalescent plasma treatment. These were reminders that the agency Americans trust to protect the public does get things wrong sometimes and is susceptible in some ways to political press

United statesJeff shurenCenters for diseaseLaboratory developedDrug administration reauthorization actNational evaluation systemHuman servicesDrug administrationTrump administrationBreakthrough devices programDigital health centerDigital healthRadiological healthSenate democratsDepartment of healthSafer technologies program